Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization
about
Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43GADD45 proteins: central players in tumorigenesisOvarian cancer standard of care: are there real alternatives?Current status and evolution of preclinical drug development models of epithelial ovarian cancerNanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancerIn vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.The biology of ovarian cancer: new opportunities for translationSecreted frizzled-related protein 4: an angiogenesis inhibitor.KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.Factors promoting tumor angiogenesis.Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.Angiogenesis in epithelian ovarian cancer.Anti-proliferative and angio-suppressive effect of Stoechospermum marginatum (C. Agardh) Kutzing extract using various experimental modelsCombinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.Vascular endothelial growth factor in ovarian cancer.Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas.Angiogenesis and reproduction.Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies.Napoleone Ferrara and the saga of vascular endothelial growth factor.A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity.Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.VEGF blocking therapy in the treatment of cancer.Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer.Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI.Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Generation and characterization of an ascitogenic mesothelin-expressing tumor model.Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts.Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancerGeneration of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.Management of ascites due to gastrointestinal malignancy.
P2860
Q21254678-B15436EB-B027-48BB-B918-FC9E06856BD5Q24608649-3E940D99-07BF-4379-B258-D0E2C4EEBDE4Q26862249-8082F1BA-BC9E-4FE3-BF18-A810440EC86DQ27028117-C68079E2-8247-4399-8A9C-3C6DCAD4B328Q27318677-356E44A1-DA8D-44F0-AF58-DEA8FFB750C7Q28482047-5E6DD209-B279-40F0-B733-246EACDC7FF6Q30405727-F506E862-565B-4E30-BEC8-A86027086D37Q33404538-C54B3142-FD27-4CEF-AA31-2CAECB86261DQ33622369-19AFF44F-B688-4567-A821-9C73D2110C22Q33703825-1946F6B4-6E86-4464-9C4F-F41A9B9BC3CBQ33712835-1B1CA2AF-262E-434C-B75F-56B9F60A5AC8Q33771212-263A00A4-3BB2-4359-B6C9-61215877A11FQ33791689-8A539231-3A5B-4413-93D4-1885A04D7713Q33884456-D2F8A886-2CF9-4CBF-997C-BFC68718F995Q33914512-B61E1D28-A2FE-4C44-86C3-F436A5FF2E00Q33919078-B49903C2-7999-4659-844E-562C49D65212Q34006393-8DF04DD3-10A8-4250-B195-F85D29ABBAA1Q34023344-607BB171-41C5-4A6F-A315-54C8449971E2Q34023497-8DAE8C92-89DE-44D4-86D2-4DA234F34DC2Q34107669-C24D312F-D37B-456A-920B-E1BA21C8B23EQ34131954-54C5A6FB-1A1B-48E0-AB38-8DCF428DB70FQ34139923-DF26F80B-5727-4536-9ADE-69F8FDCD4205Q34265171-EFB4F9EA-8358-462C-8CF0-B420607119DCQ34340220-58DC2711-D45A-4121-98BE-C40A3FDAD809Q34514125-649EC92B-675C-4A2D-82DB-ED99A61918BBQ34787946-2071A962-14A1-4DF6-BE0E-FC79E06FF22AQ34836822-0AC3501B-C955-46DE-92CF-5DE3757F3B5DQ35022254-4B1027F0-6A14-4A08-9091-F72EAC62B647Q35093616-9529695C-906E-4D96-9981-9C3BD7C26026Q35094484-DDAC9D2F-22E5-43C9-8464-53791D85A1DEQ35163538-6764D7E0-50CC-477B-9B47-E0C2C4C8C83DQ35180077-E1EE9D55-0F12-4C8F-AF8A-1E1C6CBC3DB7Q35201734-36242576-1E16-49EA-A66D-2F5129F6B36BQ35233993-64B39EAB-7367-47C2-9B4B-111F48D1F047Q35236067-85D0EF75-5459-4C8D-A208-599914B6DB26Q35747351-57E6E1CE-EF41-4E0C-8A8A-8D5EFBB99654Q35747792-B7788531-8A8C-4980-8820-994793D9A2DEQ35748149-D71334F8-4612-48DC-9520-3DB08CBD19CCQ35750289-36277A7E-133F-49E1-BCE9-24DDE38F36BBQ35789515-DD111172-DFE9-43E2-8488-DF092DAE4AC9
P2860
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Role of vascular endothelial g ...... mation by immunoneutralization
@ast
Role of vascular endothelial g ...... mation by immunoneutralization
@en
type
label
Role of vascular endothelial g ...... mation by immunoneutralization
@ast
Role of vascular endothelial g ...... mation by immunoneutralization
@en
prefLabel
Role of vascular endothelial g ...... mation by immunoneutralization
@ast
Role of vascular endothelial g ...... mation by immunoneutralization
@en
P2093
P2860
P1476
Role of vascular endothelial g ...... mation by immunoneutralization
@en
P2093
P2860
P304
P356
10.1016/S0002-9440(10)65669-6
P407
P577
1998-10-01T00:00:00Z